Isolated nucleic acid molecule encoding murine Anti-CD19 chimeric antigen receptor for treating cancer, vector and cell thereof

The engineered mouse anti-CD19 CAR-T cells, with specific antibody and signaling domains, improve cancer therapy efficacy by enhancing T cell targeting and cytotoxicity, resulting in better disease-free survival in leukemia models.

JP2024160965AInactive Publication Date: 2024-11-15PELL BIO MED TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024072668
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-04-26
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing chimeric antigen receptor-T (CAR-T) cells for cancer therapy are not sufficiently effective, necessitating improved targeting and cytotoxicity against tumor cells.

Method used

Development of a mouse anti-CD19 chimeric antigen receptor comprising specific antibody domains, costimulatory and intracellular signaling domains, encoded by nucleic acid molecules and delivered via vectors like lentiviral vectors, to enhance T cell efficacy.

Benefits of technology

The engineered CAR-T cells demonstrate enhanced degranulation, cytotoxicity, and proliferation against CD19+ cancer cells, leading to improved disease-free survival rates in leukemia xenograft models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160965000001_ABST
    Figure 2024160965000001_ABST
Patent Text Reader

Abstract

To provide an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR).SOLUTION: The CAR includes: a single chain antibody or single chain antibody fragment comprising a murine anti-CD19 binding domain, wherein the murine anti-CD19 binding domain comprises a heavy chain variable region comprising CDR H1, CDR H2 and CDR H3 and a light chain variable (VL) region comprising CDR L1, CDR L2 and CDR L3; a costimulatory domain comprising 4-1BB; and a primary intracellular signaling domain comprising a native intracellular signaling domain of CD3-ζ.SELECTED DRAWING: Figure 9
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to chimeric antigen receptors, and in particular to murine anti-CD19 chimeric antigen receptors. [Background technology]

[0002] Tumor cells have many properties that promote immune evasion. Recently, chimeric antigen receptor-T (CAR-T) have been engineered to specifically target tumor cell therapy. CAR-T is generated by genetically modifying the patient's own T cells. Through processes such as isolation, activation, genetic modification and amplification, a pre-designed gene is introduced into the patient's T cells, and the generated CAR-T simultaneously expresses a specific cancer targeting motif through its CAR structure and exhibits enhanced cytotoxicity against cancer cells. The fully prepared CAR-T is then reinjected into the patient's body to treat the cancer.

[0003] Despite the above efforts, the need for more effective CAR-T continues, and therefore improvements on the current technology are necessary. Summary of the Invention [Means for solving the problem]

[0004] One embodiment of the present disclosure provides an isolated nucleic acid molecule encoding a chimeric antigen receptor, the chimeric antigen receptor being a single chain antibody or single chain antibody fragment comprising a mouse anti-CD19 binding domain, the mouse anti-CD19 binding domain comprising a heavy chain variable (VH) region comprising a heavy chain complementarity determining region 1 (CDR H1), a CDR H2 and a CDR H3, and a light chain variable (VL) region comprising a light chain complementarity determining region 1 (CDR L1), a CDR L2 and a CDR L3, wherein CDR H1 comprises SEQ ID NO: 1, CDR H2 comprises SEQ ID NO: 2, CDR H3 comprises SEQ ID NO: 3, CDR L1 comprises SEQ ID NO: 4, CDR L2 comprises SEQ ID NO: 5 and CDR L3 comprises SEQ ID NO: 6, a costimulatory domain comprising 4-1BB, and a CD3-ζ (CD3 and a primary intracellular signaling domain that comprises the native intracellular signaling domain of zeta.

[0005] In some embodiments, the murine anti-CD19 binding domain is a single-chain variable fragment (scFv), a two-chain scFv, an antigen-binding fragment (Fab), or a F(ab')2.

[0006] In some embodiments, the heavy chain variable region comprises SEQ ID NO:7, or a sequence having at least 90% identity thereto, and the light chain variable region comprises SEQ ID NO:8, or a sequence having at least 90% identity thereto.

[0007] In some embodiments, the murine anti-CD19 binding domain comprises the amino acid sequence of SEQ ID NO:9, or an amino acid sequence having at least 90% identity thereto.

[0008] In some embodiments, the murine anti-CD19 binding domain comprises a nucleic acid sequence encoding a murine anti-CD19 binding domain, the nucleic acid sequence comprising SEQ ID NO: 10, or a nucleic acid sequence having at least 90% identity thereto.

[0009] In some embodiments, 4-1BB comprises the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 90% identity thereto.

[0010] In some embodiments, 4-1BB comprises a nucleic acid sequence encoding 4-1BB, wherein the nucleic acid sequence comprises SEQ ID NO: 14, or a nucleic acid sequence having at least 90% identity thereto.

[0011] In some embodiments, CD3-zeta comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 90% identity thereto.

[0012] In some embodiments, CD3-zeta comprises a nucleic acid sequence encoding CD3-zeta, wherein the nucleic acid sequence comprises SEQ ID NO: 16, or a nucleic acid sequence having at least 90% identity thereto.

[0013] In some embodiments, the chimeric antigen receptor comprises, in order, a single chain antibody or a single chain antibody fragment, a costimulatory structural domain, and a primary intracellular signaling structural domain.

[0014] In some embodiments, the isolated nucleic acid molecule encoding the chimeric antigen receptor further comprises the transmembrane domain of the CD8 hinge.

[0015] In some embodiments, the CD8 hinge comprises the amino acid sequence of SEQ ID NO:11, or an amino acid sequence having at least 90% identity thereto.

[0016] In some embodiments, the CD8 hinge comprises a nucleic acid sequence encoding a CD8 hinge, wherein the nucleic acid sequence comprises SEQ ID NO: 12, or a nucleic acid sequence having at least 90% identity thereto.

[0017] In some embodiments, the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 90% identity thereto.

[0018] In some embodiments, the chimeric antigen receptor comprises a nucleic acid sequence encoding said chimeric antigen receptor, wherein the nucleic acid sequence comprises SEQ ID NO: 18, or a nucleic acid sequence having at least 90% identity thereto.

[0019] Another embodiment of the present disclosure provides a vector comprising a nucleic acid molecule encoding the chimeric antigen receptor described above.

[0020] In some embodiments, the vector is selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, and a retroviral vector.

[0021] In some embodiments, the vector further comprises an EF-1 promoter.

[0022] Another embodiment of the present disclosure provides a cell comprising the above vector, the cell being a human T cell.

[0023] In some embodiments, the T cells are CD8+ T cells, CD4+ T cells, or a combination thereof. [Brief description of the drawings]

[0024] The various aspects of the present disclosure are best understood when read in conjunction with the following detailed description in the drawings. It should be noted that, in accordance with industry standard operating procedures, the various features may not be drawn to scale. In fact, the dimensions of the various features may be arbitrarily increased or decreased for clarity of discussion. In order to more clearly and understandably describe the above and other objects, features, advantages, and embodiments of the present disclosure, the drawings are described as follows: [Figure 1] Expression of CD19 on the surface of the Raji cancer cell line, gated on P1 using flow cytometry. [Figure 2A] Degree of CD107a degranulation in untransduced (UTD) and CAR-transduced primary T cells (CD19.BB.z) after 5 hours of co-culture with CD19+ Raji cancer cells. [Figure 2B] Extent of CD107a degranulation in non-transduced (CD4 UTD, CD8 UTD) and CAR-transduced primary T cells after 5 hours of co-culture of primary T cells, including CD4+ CAR-T subpopulations (CD4 CD19.BB.z) and CD8+ CAR-T subpopulations (CD8 CD19.BB.z), with CD19+ Raji cancer cells. [Diagram 3] Specific cell lysis measured based on luciferase (Luc)-based cytotoxicity experiments after co-culture of Raji cancer cells with non-transduced (UTD) and CAR-transduced primary T cells (mCD19) for 48 h. [Figure 4] The proliferation of CAR-transduced primary T cells is measured by flow cytometry in the absence or presence of Raji cancer cells at different E:T ratios. [Diagram 5] Figure 4 CAR-T proliferation model. [Figure 6] The study design is for a leukemia xenograft animal model. [Figure 7] Bioluminescence images of G1–G4 mice obtained at the indicated time periods under the same imaging conditions. [Figure 8] In vivo bioluminescence intensity throughout the organs (heart, liver, spleen, lungs, kidneys, brain and femur) and whole body of mice implanted with Raji / Luc cancer cells on the day of sacrifice. [Figure 9] Kaplan-Meier survival curves for CAR-T administered to the Raji / Luc cancer model. Disease-free survival curves for Burkitt lymphoma. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] In order to make the description of the present disclosure more detailed and complete, the following will exemplarily describe the embodiments and specific examples of the present disclosure, but this is not the only way to implement or operate the specific examples of the present disclosure. The embodiments disclosed below may be combined with each other when beneficial, or may be substituted, or one embodiment may be added to another without the need for further description or explanation. In the following description, many specific details are described in detail to allow the reader to fully understand the following examples. However, the embodiments of the present disclosure may be implemented without such specific details.

[0026] As used herein, unless otherwise limited by the articles, "a," "an," and "the" can generally refer to the singular or the plural. As will be further understood, as used herein, "comprise," "contain," "have," and similar words refer to the stated features, regions, integers, steps, operations, elements, and / or components, but do not exclude said or additional one or more other features, regions, integers, steps, operations, elements, components, and / or groups thereof.

[0027] In some embodiments, the CAR of the isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprises a single chain antibody or single chain antibody fragment, the single chain antibody or single chain antibody fragment comprises a mouse anti-CD19 binding structural domain, the transmembrane domain comprises a CD8 hinge, the costimulatory structural domain comprises 4-1BB, and the primary intracellular signaling structural domain comprises the native intracellular signaling structural domain of CD3-zeta.

[0028] In some embodiments, the murine anti-CD19 binding domain comprises a heavy chain variable (VH) region comprising heavy chain complementarity determining region 1 (CDR H1), CDR H2 and CDR H3, and a light chain variable (VL) region comprising light chain complementarity determining region 1 (CDR L1), CDR L2 and CDR L3. CDR H1 comprises SEQ ID NO: 1, CDR H2 comprises SEQ ID NO: 2, CDR H3 comprises SEQ ID NO: 3, CDR L1 comprises SEQ ID NO: 4, CDR L2 comprises SEQ ID NO: 5 and CDR L3 comprises SEQ ID NO: 6. The CDR regions are defined by the Kabat definition.

[0029] In some embodiments, the full length of the heavy chain variable region comprises SEQ ID NO:7 and the full length of the light chain variable region comprises SEQ ID NO:8, or a sequence with at least 90% identity thereto.

[0030] In some embodiments, the full length single chain variable fragment (scFv) of the murine anti-CD19 binding domain comprises the amino acid sequence of SEQ ID NO:9, or an amino acid sequence having at least 90% identity thereto.

[0031] In some embodiments, the murine anti-CD19 binding domain comprises a nucleic acid sequence encoding a murine anti-CD19 binding domain, the nucleic acid sequence comprising SEQ ID NO: 10, or a nucleic acid sequence having at least 90% identity thereto.

[0032] In some embodiments, the CD8 hinge comprises the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 90% identity thereto. In some embodiments, the CD8 hinge comprises a nucleic acid sequence encoding the CD8 hinge, wherein the nucleic acid sequence comprises SEQ ID NO: 12, or a nucleic acid sequence having at least 90% identity thereto.

[0033] In some embodiments, 4-1BB comprises the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 90% identity thereto. In some embodiments, 4-1BB comprises a nucleic acid sequence encoding 4-1BB, wherein the nucleic acid sequence comprises SEQ ID NO: 14, or a nucleic acid sequence having at least 90% identity thereto.

[0034] In some embodiments, CD3-zeta comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 90% identity thereto. In some embodiments, CD3-zeta comprises a nucleic acid sequence encoding CD3-zeta, wherein the nucleic acid sequence comprises SEQ ID NO: 16, or a nucleic acid sequence having at least 90% identity thereto.

[0035] In some embodiments, the full length of the CAR comprises the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence with at least 90% identity thereto. In some embodiments, the full length of the CAR comprises a nucleic acid sequence encoding the CAR, wherein the nucleic acid sequence comprises SEQ ID NO: 18, or a nucleic acid sequence with at least 90% identity thereto.

[0036] In some embodiments, for nucleic acid sequences having at least 90% identity to SEQ ID NOs: 10, 12, 14, 16, and 18, sequences having 90% to 99% identity to SEQ ID NOs: 10, 12, 14, 16, and 18, respectively, can provide similar benefits in this embodiment, such as 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or any value between any two of these values.

[0037] In some embodiments, the nucleic acid sequence is selected from degenerate sequences of SEQ ID NOs: 10, 12, 14, 16, and 18. The term "degenerate sequence" refers to a nucleic acid sequence in which some of the nucleotides are substituted. In other words, the degenerate sequences of SEQ ID NOs: 10, 12, 14, 16, and 18 mean that when the sequence lengths of SEQ ID NOs: 10, 12, 14, 16, and 18 are constant, about 1% to 10% variation from the oligonucleotide sequence can be tolerated.

[0038] In some embodiments, the nucleic acid sequence is selected from a derivative of SEQ ID NO: 10, 12, 14, 16, and 18. The term "derived sequence" means that the 3' and / or 5' ends of the oligonucleotide sequence of the present disclosure have been modified, and part or all of the oligonucleotide sequence can be retained.

[0039] The term "homologous" or "identity" refers to the identity of subunit sequences between two polymeric molecules (e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or two polypeptide molecules). Two molecules are homologous or identical at a subunit position if both are occupied by a similar monomeric subunit, e.g., if each position in two DNA molecules is occupied by adenine. The homology between two sequences is directly related to the number of matching or homologous positions, e.g., if half of the positions in the two sequences are homologous (e.g., five positions in a polymer ten subunits long), the two sequences are 50% homologous, and if 90% of the positions (e.g., nine out of ten) are homologous or identical, the two sequences are 90% homologous.

[0040] In some embodiments, the disclosure relates to a vector comprising a nucleic acid sequence encoding a CAR. In one embodiment, the vector is selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector.

[0041] In some embodiments, the vector is a lentiviral vector. In one embodiment, the vector further comprises a promoter. In some embodiments, the promoter is an EF-1 promoter. In some embodiments, the promoter is an EF-1 alpha promoter. In some embodiments, the vector is an in vitro transcribed vector.

[0042] In some embodiments, the cell comprises the vector described above. In one embodiment, the cell is a human T cell. In some examples, the T cell is a CD8+ T cell.

[0043] The mouse anti-CD19 chimeric antigen receptor of the present disclosure will be described in more detail below with reference to several examples and experimental examples. However, these are merely illustrative and are not intended to limit the present disclosure, and the scope of protection of the present disclosure is subject to that defined in the claims below.

[0044] Working Example

[0045] Although the methods of the present disclosure are described below using a sequence of operations or steps, the order in which these operations or steps are shown should not be construed as a limitation of the present disclosure. For example, some operations or steps can be performed in different orders and / or simultaneously with other steps. Moreover, it is not necessary to perform all illustrated operations, steps, and / or features to realize an embodiment of the present disclosure. Moreover, each operation or step described herein can include multiple sub-steps or sub-operations.

[0046] Example 1 Generation of lentivirus

[0047] Lentiviruses were the key materials for generating CAR-T cells. They were used to transduce specially designed CAR plasmid sequences into human T cells to generate T cells expressing the CAR.

[0048] To prepare cells for lentivirus production, attached 293T cells cultured in culture flasks were isolated with trypsin. After trypsinization of FBS-containing medium was stopped, 293T cells were collected by centrifugation and resuspended in 293T medium (DMEM with 10% FBS, 2 mM glutamine and 1 mM pyruvate). Cells were stained using acridine orange / propidium iodide, and cell counting was performed automatically using a LUNA-FL™ automated fluorescent cell counter (abbreviated as AO / PI and cell counter) to determine the number and viability of 293T cells. When 293T cells in T875 culture flasks were used to produce lentivirus, 1.5×10 7 The cells were resuspended in 200 milliliters (mL) of medium, mixed evenly, and transferred to a T875 culture flask. The T875 containing the cells was then incubated at 37° C. / 5% CO 2 The cells were cultured in a humidified incubator.

[0049] After 3 days of culture, lentivirus packaging was initiated by co-culturing 293T cells with the transfection reagent Polyjet™ and medium containing four single DNA plasmids genetically engineered with GAG-Pol, Rev, VSV-G, CD19 (including the above mouse anti-CD19 binding domain, CD8 hinge, 4-1BB, and CD3-ζ), with or without the fifth DNA plasmid TAT. The establishment of DNA plasmids was mainly modified with molecular cloning technology by custom synthesis, and the transfection process was carried out using the transfection reagent Polyjet™ according to the manufacturer's protocol. The original medium of 293T was aspirated and replaced with 108 mL of serum-free DMEM containing 8 mL of PolyJet / DNA premix. The T875 was then incubated at 37°C / 5% CO 2 The cells were then transfected by placing them in a humidified incubator at 4 °C.

[0050] After 12–18 h of transfection, the cell cultures were rinsed with PBS and supplemented with 100 mL of OPTI-MEM medium (Opti-MEM, 2 mM glutamine, 1 mM pyruvate, 0.25% albumin, and 20 mM HEPES) to harvest the supernatant containing the lentivirus. To continuously produce and harvest lentivirus, the T875 was incubated at 37 °C / 5% CO 2 The cells were cultured in a humidified incubator at 37 °C for 24 h. Specifically, the lentivirus-containing supernatant was collected once or twice every 24 h and replaced with 100 mL of fresh OPTI-MEM medium after each collection.

[0051] Each time the supernatant containing lentivirus was collected, it was clarified with a 0.45 μm filter cup and temporarily stored at 4°C. Based on the manufacturer's instructions, the lentivirus sample was further purified with a tangential flow filtration (TFF) device KrosFlo®, buffer exchange and concentration. Using a lentivirus sample driven by pressure generated by a sterile container, tube, hollow fiber, and peristaltic pump connected in a specific procedure, potential contaminants in the lentivirus, such as cells and cell debris, were purified, and the lentivirus was exchanged into a buffer and concentrated to a higher concentration so that it was more suitable for transduction of T cells. The lentivirus processed by TFF was sterilized with a 0.2 μm filter paper and stored at -80°C.

[0052] The CD19 CAR construct comprised a single chain antibody comprising a mouse anti-CD19 binding domain, a transmembrane domain, a costimulatory domain, and a primary intracellular signaling domain. The mouse anti-CD19 binding domain comprised a heavy chain variable region and a light chain variable region. The heavy chain variable region comprised CDR H1 (SEQ ID NO: 1), CDR H2 (SEQ ID NO: 2), and CDR H3 (SEQ ID NO: 3), and the light chain variable region comprised CDR L1 (SEQ ID NO: 4), CDR L2 (SEQ ID NO: 5), and CDR L3 (SEQ ID NO: 6). The full length of the heavy chain variable region comprised SEQ ID NO: 7, and the full length of the light chain variable region comprised SEQ ID NO: 8. The full length of the scFv of the mouse anti-CD19 binding domain comprised the amino acid sequence of SEQ ID NO: 9, and the nucleic acid sequence encoding the mouse anti-CD19 binding domain was SEQ ID NO: 10. The transmembrane domain was a CD8 hinge, and the CD8 hinge comprised the amino acid sequence of SEQ ID NO: 11, and the nucleic acid sequence encoding the CD8 hinge was SEQ ID NO: 12. The costimulatory structural domain was 4-1BB, which comprised the amino acid sequence of SEQ ID NO: 13, and the nucleic acid sequence encoding 4-1BB was SEQ ID NO: 14. The primary intracellular signaling structural domain was the native intracellular signaling structural domain of CD3-ζ, which comprised the amino acid sequence of SEQ ID NO: 15, and the nucleic acid sequence encoding CD3-ζ was SEQ ID NO: 16. The full length CAR comprised the amino acid sequence of SEQ ID NO: 17, and the nucleic acid sequence encoding CAR was SEQ ID NO: 18.

[0053] Example 2 Generation of CAR-T

[0054] Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples of healthy patients using Ficoll®-Paque Premium density gradient medium and SepMate™ according to the manufacturer's protocol. After isolation, PBMCs were diluted at 2 × 10 in PBS containing 2% human albumin. 7 Cells / mL ~ 5 x 10 7 The cells were resuspended at a cell density of 10 cells / mL.

[0055] To identify PBMCs, cells were stained using AO / PI and a cell counter to determine cell size, viability, and total number. To quantify the number of T cells, PBMCs were stained using DuraClone IM Phenotyping BASIC tubes and analyzed for their CD3+ cell percentage (%) by flow cytometry (CytoFLEX).

[0056] To isolate and activate T cells from the resuspended PBMC samples, Dynabeads® magnetic beads were added to the PBMC cell suspension, with the amount added being determined based on the total number of CD3+ T cells to meet a specific Dynabeads® to T cell ratio. The mixed Dynabeads® and PBMC samples were gently spun and placed in a magnetic holder to select the beads and cells to form magnetic bead-cell complexes. The cell suspension buffer of PBS with 2% human albumin was then replaced with complete X-VIVO™ 15 medium for T cell culture.

[0057] The total number of T cells isolated with Dynabeads® was quantified (by AO / PI and cell counter) and T cells (magnetic bead-cell complexes) were counted at 1 × 10 6 The T cells were seeded into a culture flask at a cell density of 1000 cells / mL, and the culture flask containing the T cells was incubated at 37°C / 5% CO 2 The cells were then cultured overnight in a humidified incubator.

[0058] After overnight culture, pre-titered lentivirus was thawed and added to the culture flask containing the T cells and mixed with the medium by gentle pipetting at least 20 times. The culture flask was incubated at 37°C / 5% CO 2 The cells were then returned to a humidified incubator for lentiviral transduction and further expansion of the T / CAR-T cells.

[0059] After 2 days of culture, the magnetic beads were fixed using a magnetic fixation device, and the cells on the magnetic beads were rinsed with pre-existing medium to separate the Dynabeads® from the magnetic beads-cell complex. To ensure complete separation of the magnetic beads from the cells and to minimize contamination of the cell product with the magnetic beads, the bead removal process was repeated multiple times. Then, the cell size characteristics, viability and total number of the separated CAR-T cells were examined using AO / PI staining and cell counter.

[0060] CAR-T cells were expanded for an additional 4 days using the G-Rex® 10M fast-growing cell culture system. 6 CAR-T cells were added to the G-Rex® and cultured in 100 mL of complete X-VIVO™ 15. The G-Rex® containing the CAR-T cells was incubated at 37° C. / 5% CO 2 The cells were then placed in a humidified incubator and cultured for 4 days.

[0061] After 4 days of culture in G-Rex®, the G-Rex® was inverted to mix, and the amplified CAR-T was sampled with a syringe and a three-way valve. AO / PI staining and a cell counter were used to quantify the total number of CAR-T cells for calculating the fold amplification. To determine the percentage of T cells, more specifically, the percentage of CAR-T cells, the cells were not only stained and analyzed for the percentage (%) of CD3+ cells with DuraClone IM Phenotyping BASIC tubes, but also measured for the percentage (%) of CAR+ cells with a biotinylated α-mouse F(ab')2 antibody, both of which were quantified by flow cytometry (CytoFLEX). The resulting characterized CAR-T cells were then used in various experiments.

[0062] Example 3 CAR-T activation and toxicity

[0063] The process of CD107a degranulation involves the fusion of the granule membrane with the plasma membrane of immune effector cells, resulting in the surface exposure of lysosome-associated proteins. These lysosome-associated proteins, such as CD107a, are generally located in the lipid bilayer surrounding lytic granules. Therefore, expression of CD107a on the plasma membrane can be used as a marker for immune cell activation and degranulation of cytotoxicity.

[0064] The Raji cancer cell line is CD19+, and the surface expression rate of CD19 reached 99.96% when P1 gating was performed by flow cytometry (Figure 1). Raji cancer cells were cultured with non-transduced or CAR-transduced primary T cells at different effector to target (E:T) ratios (0.3:1, 1:1, 3:1, and 10:1) for 5 h, and obvious CD107a degranulation was observed only in CAR-transduced T cells (Figure 2A). The CD4+CAR-T cell subpopulation appeared to have a more obvious degranulation effect than the CD8+CAR-T subpopulation (Figure 2B).

[0065] Luciferase-based cytotoxicity experiments showed that over 20%, 40%, and 80% of CD19+Raji cancer cells were lysed when co-cultured with CAR-transduced T cells for 48 h at E:T ratios of 1:1, 3:1, and 10:1, respectively (Figure 3). Cytotoxicity was enhanced at higher E:T ratios, with a clear dose-dependent effect.

[0066] Example 4 CAR-T proliferation

[0067] CAR-T cells were stained with carboxyfluorescein succinimidyl ester (CFSE) as a marker at baseline, and after contacting with Raji cancer cells at different E:T ratios starting from 72 hours and continuing for 6 days, the decrease in CFSE intensity and the proliferation status of CAR-transduced T cells were observed. After contacting with Raji cancer cells, obvious CAR-T proliferation was observed (Figure 4), indicating the mode of CAR-T cell division (FCS Express™ 7, De Novo Software, CA, USA) (Figure 5).

[0068] Example 5 Leukemia xenograft animal model

[0069] Raji / Luc cancer cells were inoculated into the tail vein (1 × 10 6 Mice were injected with 100 μl / cell (100 μL / mouse) of CAR-T cells. On day 7 (D7), mice were injected intravenously (iv) once with CAR-T cells. Tumor progression was monitored by bioluminescence imaging (BLI) on the scheduled days. Mouse weight and clinical sign observations were recorded weekly. CAR-T cell persistence was monitored weekly by fluorescence activated cell sorting (FACS). Luciferase activity (Figure 6) was measured in organs (heart, liver, spleen, lung, kidney, brain, and femur) by BLI.

[0070] Table 1 shows the grouping and administration. The first block factor for the Raji / Luc cancer cell injection group was the body weight of the mice. Based on the body weight, the mice were divided into 10 levels (from low to high, 4 mice per level). The mice at each level were randomly divided into each group. The second block factor for the CAR-T cell injection group was the bioluminescence signal. Based on the bioluminescence signal, the mice were divided into 10 levels (from low to high, 4 mice per level). The mice at each level were randomly divided into each group.

[0071] [Table 1]

[0072] See Figure 7, which shows bioluminescence images of G1-G4 mice obtained at the indicated time periods under the same imaging conditions. The symbols X, ▲, and ● represent the humane endpoints at D17-D25 (most mice developed paralysis), D28-D56 (most mice lost weight), and D56 (survival), respectively. The mean bioluminescence intensity of each group (x10 3 , photons / sec / cm 2 / sr) are shown in Table 2.

[0073] [Table 2]

[0074] The results showed that the saline group mice in group G1 died within 2-3 weeks after the Raji cancer cells were injected. Conversely, when the E:T ratio was high, the bioluminescence intensity decreased obviously dose-dependently from the first week to the third week, among which most mice died with paralysis symptoms due to cancer between D17 and D25 (shown by symbol x in Figure 7). Between D28 and D56, most mice died with weight loss due to graft-versus-host disease (GVHD, commonly referred to as rejection) (shown by symbol ▲ in Figure 7), which was further evidenced by pathological sections. As shown in group G4, the decrease in bioluminescence intensity from the first week to the second week indicated that the tumor was reduced in the early weeks, but between D28 and D56, most mice died with weight loss due to GVHD.

[0075] Figure 8 shows the in vivo bioluminescence intensity of the organs (heart, liver, spleen, lung, kidney, brain, and femur) and whole body of the Raji / Luc cancer cell-implanted mice on the day of sacrifice. The mean value of the bioluminescence intensity (photons / sec / cm) of the designated organs of each group on the day of sacrifice. 2 / sr) are shown in Table 3.

[0076] [Table 3]

[0077] The results showed that the bioluminescence intensity represented the distribution of Raji cancer cells throughout the body, including the heart, liver, spleen, lung, kidney, brain and femur. The bioluminescence intensity of all organs was all decreased at high E:T ratios, with obvious dose-dependent effects.

[0078] As shown in Figure 9, Figure 9 is the Kaplan-Meier survival curve of the Raji / Luc cancer model administered with CAR-T. To analyze the actual survival rate after CAR-T administration, mice that died due to GVHD were excluded. In the disease-free survival curve of Burkitt lymphoma, all mice in the G1 group administered with saline only died 24 days after Raji cancer cell transplantation. In contrast, the survival rate of the G2 group with E:T=1:1 was 25%, the survival rate of the G3 group with E:T=3:1 was 70%, and surprisingly, the survival rate of the G4 group with E:T=10:1 within 28 days after Raji cancer cell transplantation was 100%.

[0079] Although the present disclosure has been disclosed in the above-mentioned embodiments, they are not used to limit the present disclosure, and any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure, so the scope of protection of the present disclosure is based on those defined by the claims attached later.

Claims

1. 1. An isolated nucleic acid molecule encoding a chimeric antigen receptor, said chimeric antigen receptor comprising: a heavy chain variable region comprising heavy chain complementarity determining region 1, heavy chain complementarity determining region 2 and heavy chain complementarity determining region 3; a mouse anti-CD19 binding domain comprising a light chain variable region comprising a light chain complementarity determining region 1, a light chain complementarity determining region 2 and a light chain complementarity determining region 3; a single-chain antibody or single-chain antibody fragment, wherein the heavy chain complementarity determining region 1 comprises SEQ ID NO:1, the heavy chain complementarity determining region 2 comprises SEQ ID NO:2, the heavy chain complementarity determining region 3 comprises SEQ ID NO:3, the light chain complementarity determining region 1 comprises SEQ ID NO:4, the light chain complementarity determining region 2 comprises SEQ ID NO:5, and the light chain complementarity determining region 3 comprises SEQ ID NO:6; A costimulatory structural domain comprising 4-1BB; a primary intracellular signaling structural domain comprising the native intracellular signaling structural domain of CD3-ζ; 1. An isolated nucleic acid molecule encoding a chimeric antigen receptor comprising:

2. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the mouse anti-CD19 binding domain is a single-chain variable fragment, a two-chain variable fragment, an antigen-binding fragment, or F(ab')2.

3. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the heavy chain variable region comprises SEQ ID NO:7 or a sequence having at least 90% identity thereto, and the light chain variable region comprises SEQ ID NO:8 or a sequence having at least 90% identity thereto.

4. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the mouse anti-CD19 binding domain comprises the amino acid sequence of SEQ ID NO:9, or an amino acid sequence having at least 90% identity thereto.

5. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the murine anti-CD19 binding domain comprises a nucleic acid sequence encoding the murine anti-CD19 binding domain, the nucleic acid sequence comprising SEQ ID NO: 10, or a nucleic acid sequence having at least 90% identity thereto.

6. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the 4-1BB comprises the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 90% identity thereto.

7. The isolated nucleic acid molecule encoding a chimeric antigen receptor of claim 1, wherein the 4-1BB comprises a nucleic acid sequence encoding the 4-1BB, the nucleic acid sequence comprising SEQ ID NO: 14, or a nucleic acid sequence having at least 90% identity thereto.

8. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the CD3-ζ comprises the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 90% identity thereto.

9. 2. The isolated nucleic acid molecule encoding a chimeric antigen receptor of claim 1, wherein the CD3-ζ comprises a nucleic acid sequence encoding the CD3-ζ, the nucleic acid sequence comprising SEQ ID NO: 16, or a nucleic acid sequence having at least 90% identity thereto.

10. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises, in order, the single chain antibody or the single chain antibody fragment, the costimulatory structural domain, and the primary intracellular signaling structural domain.

11. 2. An isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, further comprising the transmembrane domain of a CD8 hinge.

12. 12. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 11 , wherein the CD8 hinge comprises the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 90% identity thereto.

13. 12. The isolated nucleic acid molecule encoding a chimeric antigen receptor of claim 11 , wherein the CD8 hinge comprises a nucleic acid sequence encoding the CD8 hinge, the nucleic acid sequence comprising SEQ ID NO: 12, or a nucleic acid sequence having at least 90% identity thereto.

14. 2. The isolated nucleic acid molecule encoding the chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 90% identity thereto.

15. 2. The isolated nucleic acid molecule encoding a chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises a nucleic acid sequence encoding the chimeric antigen receptor, the nucleic acid sequence comprising SEQ ID NO: 18, or a nucleic acid sequence having at least 90% identity thereto.

16. A vector comprising a nucleic acid molecule encoding the chimeric antigen receptor of claim 1.

17. 17. The vector of claim 16, wherein the vector is selected from the group consisting of DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, and a retroviral vector.

18. The vector of claim 16, further comprising an EF-1 promoter.

19. A cell comprising the vector of claim 16, said cell being a human T cell.

20. 20. The cell of claim 19, wherein the T cell is a CD8+ T cell, a CD4+ T cell, or a combination thereof.